Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
Purpose: With increasing environmental pollution, the incidence of allergic conjunctivitis is increasing. Newer anti-allergic medications with combined anti-histaminic and mast cell stabilization action can help reducing the use of topical steroids for milder form of disease. There is no study direc...
Main Authors: | Lakshey Dudeja, Anuja Janakiraman, Ishani Dudeja, Kaustubh Sane, Manohar Babu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
Series: | Indian Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=9;spage=1400;epage=1404;aulast=Dudeja |
Similar Items
-
A comparative study of efficacy and tolerability of bepotastine besilate (1.5%) and olopatadine hydrochloride (0.1%) eye drops in allergic conjunctivitis in a tertiary care hospital of the southern part of India
by: Sudipto Chatterjee, et al.
Published: (2024-10-01) -
Efficacy and Toxicity Evaluation of Bepotastine Besilate 1.5% Preservative-Free Eye Drops Vs Olopatadine Hydrochloride 0.2% Bak-Preserved Eye Drops in Patients with Allergic Conjunctivitis
by: Marini MC, et al.
Published: (2023-11-01) -
A comparative study of efficacy and safety of alcaftadine 0.25% versus olopatadine hydrochloride 0.2% in allergic conjunctivitis at a tertiary care hospital
by: Akila Krishnan, et al.
Published: (2022-01-01) -
Determination of antihistaminic drugs alcaftadine and olopatadine hydrochloride via ion-pairing with eosin Y as a spectrofluorimetric and spectrophotometric probe: application to dosage forms
by: Sayed M. Derayea, et al.
Published: (2024-02-01) -
Clinical Experience of Using 0.2 % Olopatadin in the Allergic Conjunctivitis Treatment
by: S. V. Yanchenko, et al.
Published: (2019-10-01)